Interviews

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.

Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.

Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.

Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses a population-based study of incidence and survival trends of 1261 thymic malignancies from the California Cancer Registry.

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses continued angiogenesis suppression following progression on bevacizumab in metastatic colorectal cancer (mCRC).

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of a phase I study of AZD4547 in patients with advanced tumors.

Melanie B. Thomas, MD, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of IPMN and pancreatic cancer.

Sean C. Dowdy, MD, professor, chair, Division of Gynecologic Surgery, co-leader, Women’s Cancer Program, Mayo Clinic, discusses bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Lori J. Wirth, MD, discusses the results from the phase III SELECT trial that analyzed lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer. There were 6 treatment-related deaths on the study.

Halle Moore, MD, discusses a phase III trial that looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.

Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).

Luiz H. Araujo, MD, medical oncologist, Corporate Cancer Foundation fellow, Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, discusses the discovery of oncogenic ARAF as a new driver for lung cancer.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the updated overall survival analysis of the phase III DECISION trial, which looked at sorafenib for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC).

Adam M. Brufsky, MD, PhD, discusses the results of a study that looked at the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or MBC.

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the RESONATE trial, a phase III trial that compared ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma.

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).

Daniel P. Petrylak, MD, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC).

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in patients with early-stage breast cancer.

Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Translational and Outcomes Research, Section of Urology, University of Chicago, discusses the adoption of robot-assisted surgery and its impact on treatment patterns for newly diagnosed localized prostate cancer patients.

Gregory J. Riely, MD, PhD, vice chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses the impact of the stigma of cigarette smoking on lung cancer research.

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index and prostate cancer risk.

Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses the advantages and limitations of nipple-sparing mastectomy.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing treatment with sorafenib.

Peter T. Scardino, MD, FACS, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.

Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, describes lung suffusion.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib’s approval for patients with mantle cell lymphoma (MCL).